1. Introduction {#sec1}
===============

Obesity, hypertension, and metabolic syndrome (type 2 diabetes mellitus) are major and growing health problems and are known as high-risk factors for subsequent cardiovascular and renal complications \[[@B1]--[@B3]\]. Obesity, hypertension, diabetes, and metabolic syndrome are intimately associated \[[@B4]--[@B6]\], and sympathetic nervous activation is frequently observed in those conditions. Thus, sympathetic nerve activation may play a major role in the onset and development of hypertension, obesity, and metabolic syndrome (diabetes mellitus) as well as cardiovascular complications in patients with hypertension, diabetes and obesity \[[@B2], [@B7]\].

The sympathetic nervous system plays an important role in the regulation of energy expenditure. Reduced energy expenditure and resting metabolic rate are predictive of weight gain (obesity). The sympathetic nervous system participates in regulating energy balance through thermogenesis \[[@B8]\]. A large part of the sympathetic nervous system-mediated energy expenditure takes place in skeletal muscle, via the coupling of catecholamines with *β*2-adrenoceptors. Catecholamines are also powerful regulators of lipolysis and act via *β*1-, *β*2-, *β*3- (stimulatory), and *α*2- (inhibitory) adrenoceptor subtypes in adipose tissue, where their role becomes especially important during both exercise and energy restriction, when increased need for fat as a fuel exists. Thus, *β*-adrenoceptors play important roles in energy expenditure and control body weight \[[@B9]--[@B13]\].

Recently, there is evidence that human hypertension and obesity have strong genetic backgrounds \[[@B14]--[@B16]\]. Harrap et al. reported that about 46% of the phenotype of systolic blood pressure are determined genetically for hypertension \[[@B17], [@B18]\]. Masuo et al. \[[@B18]--[@B22]\] have reported close relationships between *β*2- and *β*3-adrenoceptor polymorphisms accompanying elevated sympathetic nervous activity, blood pressure elevation (hypertension), weight gain (obesity), and insulin resistance in a series of longitudinal study. Many epidemiological studies on the relationships between *β*-adrenoceptor polymorphisms, hypertension, obesity, and diabetes (metabolic syndrome) have still been discordant.

This paper will discuss the current topics involving the contribution of the sympathetic nervous system and *β*2- and *β*3-adrenoceptor polymorphisms in the onset and the development of hypertension and metabolic syndrome (type 2 diabetes mellitus).

2. Subtypes of Adrenoceptors ([Table 1](#tab1){ref-type="table"}) {#sec2}
=================================================================

The adrenoceptors (or adrenergic receptors) are a class of G protein-coupled receptors which specifically bind their endogenous ligands, the catecholamines (epinephrine and norepinephrine). Many tissues possess these adrenoceptors, and the binding of an agonist generally elicits a "typical" sympathetic response (i.e., the fight-or-flight response). [Table 1](#tab1){ref-type="table"} shows the effects of catecholamines bound to adrenoceptors ([Table 1](#tab1){ref-type="table"}) and these effects on sympathetic nervous activity are through *α*- and *β*-adrenergic receptors.

There are several types of adrenergic receptors, but there are two main groups: *α*-adrenoceptors (*α*1- and *α*2-adrenoceptors) and *β*-adrenoceptors (*β*1-, *β*2-, and *β*3-adrenoceptors). [Table 1](#tab1){ref-type="table"} also summaries the distributions and functions of the *α*1-, *α*2-, *β*1-, *β*2-, and *β*3-adrenoceptors \[[@B23], [@B24]\]. The *α*-receptors bind norepinephrine and epinephrine, though norepinephrine has higher affinity. Phenylephrine is a selective agonist of the *α*-adrenoceptors (both *α*1- and *α*2-receptors), thus phenylephrine is usually used to investigate the *α*-adrenoceptors function. *β*-adrenoceptors are linked to G proteins, which are linked to adenyl cyclase. *β*-adrenoceptor agonists cause the intracellular elevation of the second messenger cyclic AMP. Downstream effects of cyclic AMP include cyclic AMP dependent protein kinase, which mediates the intracellular events following hormone binding.

3. Sympathetic Nervous Activity and Insulin Resistance in Hypertension ([Figure 1](#fig1){ref-type="fig"}) {#sec3}
==========================================================================================================

Insulin resistance in hypertension has been well documented in many epidemiological and clinical studies \[[@B8], [@B26], [@B27]\]. Several investigators have reported that chronic insulin administration elevates blood pressure in rats and in humans \[[@B28]\], although insulin also has effects on vasodilation. In addition, many clinical and epidemiological studies have demonstrated the close relationships between sympathetic nerve activity, insulin resistance and hypertension \[[@B19], [@B25]--[@B31]\].

Landsberg and other investigators examined the effect of feeding and starvation on sympathetic nerve activity in the cardiac tissue of animals, noting that feeding raised sympathetic nerve activity, and starvation had the opposite effect \[[@B32]--[@B34]\]. Energy intake stimulates hyperinsulinemia and sympathetic nerve activity resulting in blood pressure elevations in a cycle to inhibit thermogenesis. Insulin-mediated sympathetic nerve stimulation in obese subjects is a compensatory mechanism aimed at restoring the energy balance by increasing the metabolic rate \[[@B32]\]. Therefore, hyperinsulinemia and insulin resistance in obese subjects are all part of a response to limit further weight gain via stimulating sympathetic nerve activity and thermogenesis \[[@B28]\].

On the other hand, Julius et al. \[[@B35]\] have hypothesized that increased sympathetic nerve activity in skeletal muscle causes neurogenic vasoconstriction, thereby reducing blood flow to muscle and consequently inducing a state of insulin resistance by lowering glucose delivery and uptake in hypertension and obesity. Both blood pressure elevation and weight gain may reflect a primary increase in sympathetic nervous tone. Masuo et al. \[[@B29], [@B36]\] supported Julius\'s hypothesis. They described that high plasma norepinephrine might predict future blood pressure elevations and weight gain accompanying deterioration in insulin resistance observed in HOMA-IR (homeostasis model assessments of insulin resistance) \[[@B29], [@B36]\]. Rocchini et al. \[[@B37]\] reported that clonidine prevented insulin resistance in obese dogs over a 6-week period. Their results suggest that sympathetic nerve activity might play a major role in the development of insulin resistance accompanying blood pressure elevations. Valentini et al. \[[@B38]\] reported attenuation of hemodynamic and energy expenditure responses to isoproterenol infusion in hypertensive patients, suggesting that sympathetic nerve activity-induced hypertension may subsequently lead to the development of obesity.

Many epidemiological studies showed close linkages of beta2- and beta3-adrenoceptor polymorphisms with obesity, hypertension, and the metabolic syndrome shown in Tables [2](#tab2){ref-type="table"}, [3](#tab3){ref-type="table"}, and [4](#tab4){ref-type="table"}. Sympathetic nervous activity is related to body weight or blood pressure through *β*-adrenoceptors. Thus, close linkages between sympathetic nerve activity and insulin resistance might depend on the *β*-adrenoceptor polymorphisms. Thus, one could speculate that the strong associations between *β*-adrenoceptor polymorphisms and insulin resistance might provide evidence that heightened sympathetic nerve activity followed by insulin resistance might play a major role in hypertension and obesity, because *β*-adrenoceptor polymorphisms might relate to insulin resistance through heightened sympathetic nerve activity ([Figure 1](#fig1){ref-type="fig"}).

4. Role of *β*-Adrenoceptor Polymorphisms in Hypertension, Obesity, and Diabetes {#sec4}
================================================================================

The sympathetic nervous system plays an important role in the regulation of energy expenditure and blood pressure regulation. A large part of the sympathetic nervous system-mediated energy expenditure takes place in skeletal muscle, via the coupling of catecholamines with *β*2-adrenoceptors. Catecholamines are also powerful regulators of lipolysis and act via *β*1-, *β*2-, *β*3- (stimulatory), and *α*2- (inhibitory) adrenoceptor subtypes in adipose tissue, where their role becomes especially important during both exercise and energy restriction, when increased need for fat as a fuel exists. Stimulation of *β*-adrenergic receptors by the sympathetic nervous system is a significant physiological modulator of pre- and postprandial energy expenditure \[[@B11]--[@B13]\] and total daily energy expenditure \[[@B9], [@B10]\].

Recent studies show that *β*-adrenoceptors are polymorphic. Single nucleotide polymorphisms might have functional consequences in terms of receptor activity and regulation and hence may contribute to the pathophysiology of hypertension and obesity. On the other hand, there are few studies on the relationships between *α*-adrenoceptor polymorphisms, hypertension, obesity, and metabolic syndrome.

4.1. *β*1-Adrenoceptor Polymorphisms {#sec4.1}
------------------------------------

The *β*1-adrenoceptor is predominantly expressed in cardiac myocytes and adipose tissue, where its activation leads to increased heart rate and contractility and stimulation of lipolysis, respectively. The two most common *β*1-adrenoceptor polymorphisms are Ser49Gly and Arg389Gly, with relative allele frequencies of 0.85/0.15 and 0.70/0.30 in the Caucasian population, respectively. The *β*1-adrenoceptor is a candidate gene for obesity because of its role in catecholamine-mediated energy homeostasis \[[@B39], [@B40]\]. For example, in obese individuals, the degree of weight loss during a very low calorie diet has been shown to correlate with changes in *β*1-adrenoceptor protein concentration in adipose tissue \[[@B39]\]. A population cohort of 761 women showed that women carrying the Gly49 genotype had greater increases in BMI over15 years compared to those with the Ser49 genotype \[[@B40]\]. Conversely, the distribution of the Arg389Gly polymorphism is similar in lean and obese subjects \[[@B41]\] and in a large cohort study including 3981 normotensive and 2518 hypertensive subjects \[[@B42]\]. The factors which might explain the discrepancy of published data are shown in the later section.

4.2. *β*2-Adrenoceptor Polymorphisms {#sec4.2}
------------------------------------

The *β*2-adrenoceptor is the dominant lipolytic receptor in white human adipose tissue \[[@B13]\] and in skeletal muscle \[[@B12]\]. It also plays an important regulatory role in the peripheral vasculature. Genetic polymorphisms of the *β*2-adrenoceptor have been associated with hypertension, obesity, and metabolic syndrome (diabetes mellitus). The most common polymorphisms are Arg16Gly, with an allele frequency of 0.40/0.60, and Gln27Glu, with an allele frequency of 0.55/0.45, in the Caucasian population. The Thr164Ile polymorphism is rare, occurring in only 3 to 5% of the general Caucasians population.

Studies of agonist stimulation in cultured cells demonstrate that Gly16 receptors have a greater reduction in numbers or enhanced downregulation when compared with Arg16 whereas the Glu27 receptor is resistant to down regulation when compared with the Gln27 variant \[[@B43]\]. A number of clinical studies have investigated the impact of these polymorphisms on vascular responsiveness \[[@B45], [@B44]\]. Gratze et al. \[[@B46]\] found that young normotensive white men homozygous for the Gly16 allele had higher blood pressure and lower peripheral vasodilation after infusion of the *β*2-agonist salbutamol. Similar results were obtained by Hoit et al. \[[@B47]\] using the agonist terbutaline. On the other hand, three studies investigating isoprenaline induced increase in the limb blood flow Thus, volunteers homozygous for Gly16 exhibited larger vasodilatory responses than did volunteers homozygous for Arg16 \[[@B48]\]. Conflicting results have also been published with regard to the effects of genetic variants on the sympathetic nervous system modulation of energy expenditure. Bell et al. \[[@B49]\] reported that the response of resting energy expenditure to nonspecific *β*-adrenoceptor stimulation (with isoproterenol infusion) was not different between the 3 genotypes of Arg16Gly. Stob et al. \[[@B50]\] showed that individuals carrying the Arg16Arg variant of the *β*2-adrenoceptor gene have a reduced thermogenic response to selective *β*2-adrenoceptor activation.

Associations of *β*2-adrenoceptor polymorphisms with hypertension and metabolic syndrome have been reported in many epidemiological studies but results are also discordant (summarised in Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}).

4.3. *β*3-Adrenoceptor Polymorphisms {#sec4.3}
------------------------------------

The *β*3-adrenoceptor, which is mainly expressed in adipose tissue, differs from the *β*2-adrenoceptor in two ways: it has a lower affinity for catecholamines, and it resists desensitisation (i.e., downregulation). These characteristic differences might lead to the different effects of catecholamine on *β*2-adrenoceptors and *β*3-adrenoceptors. *β*3-adrenoceptors stimulate the mobilization of lipids from the white fat cell and increase thermogenesis in brown fat cell. Decreased function of *β*3-adrenoceptor in white adipose tissue could slow lipolysis and thereby cause the retention of lipids in fat cells. Slow lipolysis may contribute strongly to visceral obesity in human, and treatment of obese animal models with selective *β*3-adrenergic agonists reduces fat stores most effectively \[[@B82], [@B81], [@B83]\]. Many epidemiological studies have shown the strong relationships between *β*3-adrenoceptor polymorphisms (mainly Trp54Arg), hypertension, metabolic syndrome, and obesity \[[@B87], [@B82], [@B81]--[@B86]\] ([Table 4](#tab4){ref-type="table"}).

4.4. Confounding Variables Affecting the Relationships of *β*-Adrenoceptor Polymorphisms with Obesity, Hypertension, and Diabetes ([Table 5](#tab5){ref-type="table"}) {#sec4.4}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Tables [2](#tab2){ref-type="table"}, [3](#tab3){ref-type="table"}, [4](#tab4){ref-type="table"}, and [5](#tab5){ref-type="table"} show the discordant contributions of *β*-adrenoceptor polymorphisms to hypertension, metabolic syndrome (type 2 diabetes), and obesity. [Table 5](#tab5){ref-type="table"} summarizes factors which might explain the discrepancy of published data. Further, haplotypes of polymorphisms have strong influence on *β*-adrenoceptor function in each polymorphism \[[@B20], [@B67], [@B68], [@B113]--[@B115]\].

5. Conclusions {#sec5}
==============

The role of the sympathetic nervous system *β*2- and *β*3-adrenoceptor polymorphisms in hypertension, metabolic syndrome (diabetes mellitus), and obesity is discussed through a literature review. Sympathetic nervous system activity and *β*-adrenoceptor polymorphisms (mainly *β*2- and *β*3-adrenoceptor polymorphisms) might contribute to the onset and maintenance of hypertension, metabolic syndrome, and obesity; however, the findings have been discordant. Further, few studies have been performed to evaluate the relationship between *β*2- and *β*3-adrenoceptor polymorphisms and sympathetic nervous system activity in the same study. A better understanding for the relationships of genetic background (polymorphisms) with sympathetic nervous system activity as the cause for hypertension (blood pressure elevation), metabolic syndrome (insulin resistance), and obesity (weight gain) might help for clinical treatment for obesity-related hypertension and metabolic syndrome. In fact, a number of studies have investigated genetic polymorphisms as determinants of cardiovascular response to antihypertensive drug therapy \[[@B116a], [@B116b]\]. But further research on gene-drug interactions is necessary. In addition, to clarify the pathogenesis and mechanisms may lead to the prevention of hypertension and metabolic syndrome in obesity.

![Potential pathophysiological mechanisms by which obesity may contribute to hypertension (modified figure from \[[@B48]\]). RAAS: renin-angiotensin-aldosterone system; SNS: sympathetic nervous system; OSA: obstructive sleep apnea; BRS, baroreflex sensitivity.](IJHT2010-832821.001){#fig1}

###### 

Comparisons of adrenergic receptor subtypes.

  Receptor type          Agonist potency order                         Action sites                                        Functions
  ---------------------- --------------------------------------------- --------------------------------------------------- ---------------------------------------
  *α* *1-adrenoceptor*   norepinephrine≥                               *blood vessels* of skim, gastrointestinal, kidney   *vasoconstriction*
                         epinephrine⋙                                  ureter, uterus, urethral sphincter, bronchioles     smooth muscle contraction,
                         isoprenaline                                  urinary bladder,                                    contraction,
                                                                       iris, blood vessels of erectile tissue,             smooth muscle relaxation,
                                                                       *heart muscle,*                                     *positive ionotropic effect*
                                                                       salivary gland,                                     increase in secretion,
                                                                       *adipose* *tissue, liver*                           *glycogenolysis and gluconeogenesis,*
                                                                       sweat glands,                                       increase in secretion,
                                                                       *kidneys*                                           *Na reabsorption*
                                                                                                                           
  **α*2-adrenoceptor*    epinephrine\>                                 pancreas and                                        *inhibition of insulin secretion,*
                         norepinephrine⋙                                                                                   *induction of glucagon release, and*
                         isoprenaline                                  gastrointestinal tract                              contraction of sphincters
                                                                                                                           
  **β*1-adrenoceptor*    isoprenaline\>                                *heart,*                                            *increase cardiac output,*
                         Norepinephrine\>                              *kidneys* (juxtaglomerular cells),                  *increase renin release, and*
                         Epinephrine                                   *adipose tissue*                                    *lipolysis*
                                                                                                                           
  **β*2-adrenoceptor*    isoprenaline\>                                Bronchi,                                            smooth muscle relaxation,
                         epinephrine≫                                  urinary sphincter, bladder wall,                    smooth muscle relaxation,
                         norepinephrine                                *skeletal muscle,*                                  *dilate arteries*
                                                                       *adipose tissue, liver*                             *glycogenolysis and gluconeogenesis,*
                                                                       gastrointestinal tract,                             contract sphincters,
                                                                       salivary glands,                                    thickened secretions,
                                                                       mast cells, and                                     inhibit histamine release, and
                                                                       *kidneys (juxtaglomerular cells)*                   *increase renin release*
                                                                                                                           
  **β*3-adrenoceptor*    isoprenaline\> norepinephrine = epinephrine   *adipose tissue*                                    *enhancement of lipolysis*

###### 

Arg16Gly, *β*2-adrenoceptor polymorphisms: association with hypertension, metabolic syndrome (type2 diabetes: (DM)), and obesity.

  Authors                                Year   Populations   Subjects                                                                           Associations with the polymorphism
  -------------------------------------- ------ ------------- ---------------------------------------------------------------------------------- ----------------------------------------------------------
  Large et al. \[[@B45]\]                1997   Swedish       140 Caucasian women with a wide range of obesity                                   Obesity
  The Quebec Family Study \[[@B50]\]     2000   Canada        Caucasian men and women                                                            Obesity, hyperlipidemia
  Hayakawa et al. \[[@B51]\]             2000   Japanese      210 Japanese men from a population                                                 No association with obesity
  Jia et al. \[[@B52]\]                  2000   USA           Caucasians (298 hypertensive versus 298 normotensive subjects)                     No association with hypertension
  Xie et al. \[[@B53]\]                  2000   USA           Black and white Americans (including normotensive and hypertensive subjects)       No associations with hypertension
  Candy et al. \[[@B54]\]                2000   English       England Black African men (including 192 hypertensive and 123 normotensive men)    No association with hypertension
  Cockcroft et al. \[[@B55]\]            2000   Caucasian     127 young normotensive men                                                         Forearm vascular responses (hypertension)
  Meirhaeghe et al. \[[@B56]\]           2000   French        1195 middle-aged Caucasian from the urban population                               Obesity, if subjects carry Gln27Gln
                                                                                                                                                 
  Kato et al. \[[@B57]\]                 2001   Japanese      842 hypertensive and 633 normotensive subjects                                     BP levels (hypertension) in normotensives
  Bengtsson et al. \[[@B58]\]            2001   Swedish       Hypertensive patients with and without type 2 DM                                   Hypertension in subjects with DM
  The Bogalusa Heart Study \[[@B59]\]    2002   USA           1151 Caucasian and Black Africans children (including boys and girls)              Weight gain in males
  Kim et al. \[[@B60]\]                  2002   Korean        type 2 DM patients                                                                 Obesity, DM, hyperlipidemia
  Chang et al. \[[@B61]\]                2002   Taiwanese     type 2 DM patients                                                                 Type 2 DM
  Van Rossum et al. \[[@B62]\]           2002   Dutch         286 subjects with a significant weight gain over 7 years including men and women   Weight gain in men, but not in women
  The HERITAGE family study \[[@B63]\]   2003   Canada        Sedentary black and white women                                                    Lower fat in obese white women
  Pereira et al. \[[@B20]\]              2003   Brazilian     1576 ethnically mixed population (including men and women)                         Systolic BP, BMI
  The Olivetti heart study \[[@B64]\]    2004   Italian       993 middle-aged men regardless of BP levels or BMI                                 No association with obesity or hypertension
  Ikarashi et al. \[[@B65]\]             2004   Japanese      type 2 diabetic patients                                                           Association with IR
  Tafel et al. \[[@B66]\]                2004   Germany       extremely obese children                                                           No association with obesity
  Ellsworth et al. \[[@B67]\]            2005   USA           Black and white American men and women                                             BMI (obesity) in only men
  Trombetta et al. \[[@B68]\]            2005   Brazilian     Brazilian healthy women                                                            Hypertension (blunted forearm vasodilation response)
  Masuo et al. \[[@B21]\]                2005   Japanese      Nonobese, normotensive men                                                         Weight gain, BP elevation, obesity-HT
  Masuo et al. \[[@B69]\]                2005   Japanese      Nonobese, normotensive men                                                         Insulin resistance
  Masuo et al. \[[@B70], [@B71]\]        2006   Japanese      Normotensive men (including nonobese and obese men)                                Weight gain, blunted leptin-sympathetic axis
  Kurabayashi et al. \[[@B72]\]          2006   Japanese      PCOS patients                                                                      Association with high prevalence of PCOS Accompanying IR
  Gjesing et al. \[[@B73]\]              2007   Dutch         7808 white subjects                                                                No association with hypertension or obesity
  Masuo et al. \[[@B74]\]                2007   Japanese      219 nonobese, normotensive men                                                     Association with high SNA followed by IR

BP: blood pressure; BMI: body mass index; HT: hypertension; DM: diabetes mellitus; IR: insulin resistance; PCOS: polycystic ovary syndrome; SNA: sympathetic nervous activity.

###### 

Gln27Glu, *β*2-adrenoceptor polymorphisms: association with hypertension, metabolic syndrome (type2 diabetes (DM)), and obesity.

  Authors \[reference number\]           Year   Populations   Subjects                                                                  Associations with the polymorphism
  -------------------------------------- ------ ------------- ------------------------------------------------------------------------- -----------------------------------------------------------------------
  Large et al. \[[@B45]\]                1997   Swedish       Caucasian women with a wide range of obesity                              Association with obesity
  Echwald et al. \[[@B75]\]              1998   Danish        Caucasian juvenile-onset obese men                                        No association with obesity
  Hellström et al. \[[@B76]\]            1999   Swedish       Caucasian men and women                                                   Association with obesity only in women
  Kortner et al. \[[@B77]\]              1999   German        Caucasian with morbid obesity                                             No association with obesity
  Xie et al. \[[@B53]\]                  2000   USA           Black and white Americans                                                 No associations with hypertension
  The Quebec Family Study \[[@B50]\]     2000   Canada        Caucasian men and women                                                   Association with obesity and hyperlipidemia
  Hayakawa et al. \[[@B51]\]             2000   Japanese      210 Japanese men from a population                                        No association with obesity
  Candy et al. \[[@B54]\]                2000   England       Black African men (including 192 hypertensive and 123 normotensive men)   No association with hypertension
  Meirhaeghe et al. \[[@B56]\]           2000   French        1195 middle-aged Caucasian in the urban population                        Association with obesity in men
  Kato et al. \[[@B57]\]                 2001   Japanese      842 hypertensive and 633 normotensive subjects                            Association with BP levels (hypertension) in NT
  Kawamura et al. \[[@B78]\]             2001   Japanese      Japanese-Americans                                                        No association with obesity or DM
  Ukkola et al. \[[@B79]\]               2002   USA           12 pairs of twins, Caucasians                                             Association with weight gain (obesity)
  Kim et al. \[[@B60]\]                  2002   Korean        Patients with type 2 DM                                                   Association with obesity, DM, and hyperlipidemia
  Gonzalez-Sanchez et al. \[[@B80]\]     2003   Spanish       666 Caucasian-based study (including men and women)                       Association with obesity only in men
  The HERITAGE family study \[[@B58]\]   2003   Canada        Sedentary black and white men                                             Association with lower fat in obese white men
  Pereira et al. \[[@B20]\]              2003   Brazilian     1576 ethnically mixed population (including men and women)                No association with systolic BP or BMI
  The Olivetti heart study \[[@B64]\]    2004   Italian       993 middle-aged men (regardless of BP levels or BMI)                      No association with obesity or hypertension
  Tafel et al. \[[@B66]\]                2004   Germany       Extremely obese children                                                  No association with obesity
  Masuo et al. \[[@B21]\]                2005   Japanese      Nonobese, normotensive men                                                Association with BP elevation, but no association with IR
  Trombetta et al. \[[@B68]\]            2005   Brazilian     Brazilian healthy women                                                   Association with hypertension (blunted forearm vasodilation response)
  Kurabayashi et al. \[[@B72]\]          2006   Japanese      PCOS women                                                                Association with high prevalence of PCOS accompanying IR
  Gjesing et al. \[[@B73]\]              2007   Dutch         7808 white subjects                                                       No association with hypertension or obesity
  Masuo et al. \[[@B74]\]                2007   Japanese      219 nonobese, normotensive men                                            No association with IR

BP: blood pressure; BMI: body mass index; DM: diabetes mellitus; NIDDM: noninsulin-dependent diabetes mellitus; IR: insulin resistance; PCOS: polycystic ovary syndrome; NT: normotensive subjects.

###### 

Trp64Arg, *β*3-adrenoceptor polymorphisms: association with hypertension, metabolic syndrome (type2 diabetes (DM)), and obesity.

  Authors \[reference number\]                                           Year   Populations         Subjects                                                                                 Associations with the polymorphism
  ---------------------------------------------------------------------- ------ ------------------- ---------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------
  Clement et al. \[[@B88]\]                                              1995   French              185 subjects with morbid obesity and                                                     Increased capacity of weight gain
                                                                                                    94 subjects with normal weight                                                           
  Widen et al. \[[@B89]\]                                                1995   Finns               335 subjects including 207 non-DM and 128 patients with NIDDM                            Insulin resistance
  Walston et al. \[[@B87]\]                                              1995   Pima Indians        390 with NIDDM and 252 without NIDDM                                                     Association with the early onset of DM2
  Fujisawa et al. \[[@B90]\]                                             1996   Japanese            Patients with NIDDM                                                                      Type 2 DM, weight gain (obesity)
  Silver et al. \[[@B91]\]                                               1996   Nauruans            65 obese subjects with NIDDM                                                             No association with DM2 or IR
  Fujisawa et al. \[[@B92]\]                                             1997   Japanese            Essential hypertension patients                                                          No association with IR during hyperinsulinemia euglycemic glucose clamp
  Sakane et al. \[[@B93]\]                                               1997   Japanese            131 obese women versus 218 controls                                                      Association with IR and obesity
  Rissanen et al. \[[@B94]\]                                             1997   Finns               110 with NIDDM, 183 with IR, and 82 controls                                             No association with NIDDM or IR
  McFarlane-Anderson et al. \[[@B95]\]                                   1998   Jamaican            Population study                                                                         Association with hyperglycemia only in women, but not in men
  Gracía-Rubi et al. \[[@B96]\]                                          1998   American            Postmenopausal women                                                                     Association with IR
  Janssen et al. \[[@B97]\]                                              1998   Dutch               Postmenopausal women                                                                     Association with IR
  Shiwaku et al. \[[@B98]\]                                              1998   Japanese            Moderate overweight men                                                                  No association with obesity
  Ongphiphadhanakul et al. \[[@B99]\]                                    1999   Thais               76 men and 135 women                                                                     No association with IR assessed by fasting insulin/glucose ratio
  Pulkkinen et al. \[[@B100]\]                                           1999   Finns               185 untreated non-DM and 119 untreated NIDDM                                             No association with IR or CHD in both non-DM and NIDDM
  Christiansen et al. \[[@B101]\]                                        1999   Danish              196 dizygotic twins                                                                      Association with lower insulin secreting capacity
  Kawamura et al. \[[@B78]\]                                             1999   Japanese-American   Japanese living in USA versus living in Japan                                            Similar distribution between Japanese-America and Japanese-Japanese. Association with IR in subjects with impaired oral glucose tolerance test.
  Stangl et al. \[[@B102]\]                                              2001   German              1000 with CHD and 1000 controls                                                          No association with prevalence of CHD or IR
  Strazzullo et al. \[[@B103]\] (The Olivetti Prospective Heart Study)   2001   Italian             979 population study                                                                     No association with IR observed in HOMA-IR
  Ishii et al. \[[@B104]\]                                               2001   Japanese            196 young normoglycemic men, 186 old normoglycemic men, and 122 old hyperglycaemic men   No association with IR or NIDDM
  Kurokawa et al. \[[@B82]\]                                             2001   Japanese            meta-analysis in 6582 subjects                                                           BMI (obesity)
  Ochoa et al. \[[@B105]\]                                               2004   Spanish             185 obese and 185 nonobese children                                                      BMI (obesity)
  Porto et al. \[[@B106]\]                                               2004   Argentina           121 NT and 54 HT from 934 high school students                                           Association with central obesity, but no association with IR
  Tsai et al. \[[@B107]\]                                                2004   Taiwanese           299 pregnant women                                                                       No association with gestational IR
  Ellsworth et al. \[[@B67]\]                                            2005   USA                 1179 African-Americans and white-Americans                                               BMI (obesity)
  Masuo K, et al. \[[@B21]\]                                             2005   Japanese            Nonobese, normotensive men                                                               BP elevation
  Masuo et al. \[[@B71]\]                                                2006   Japanese            55 obese normotensive men                                                                Weight gain (obesity), BP elevation (hypertension)
  Højlund et al. \[[@B108]\]                                             2006   Danish              10 male twins                                                                            No association between heterozygous for Trp64Arg and IR or NIDDM
  Tamaki et al. \[[@B109]\]                                              2006   Japanese            1416 population study without HT, DM, or hyperlipidemia                                  No association with metabolic syndrome
  Morcillo et al. \[[@B110]\]                                            2008   Spanish             1020 population study                                                                    Join association of alleles of -75A and Arg64 with the risk of DM
  Gjesing et al. \[[@B111]\]                                             2008   Danish              7605 population study                                                                    Association with NIDDM and IR, but no association with obesity
  Dunajska et al. \[[@B112]\]                                            2008   Polish              284 postmenopausal women                                                                 No association with metabolic syndrome

BP: blood pressure; BMI: body mass index; DM: diabetes mellitus; NIDDM: noninsulin-dependent diabetes mellitus; DM2: type 2 diabetes mellitus; IR: insulin resistance.

###### 

Confounding variables considered to cause the discrepancy of the relationships between *β*-adrenoceptor polymorphisms and phenotypes of hypertension and metabolic syndrome in obesity.

  Variables \[reference number\]                                    Findings in the studies
  ----------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Severity of obesity \[[@B16], [@B66], [@B71], [@B88], [@B105]\]   In lean subjects, *β*2-AR polymorphisms linked to obesity and obesity-related hypertension, but in obese subjects, *β*2- and *β*3-AR polymorphisms relate to obesity and obesity-related hypertension.
                                                                    Morbid obesity is linked with *β*3-AR polymorphisms, but overweight or mild obesity is not associated with those.
                                                                    
  Gender differences \[[@B80]\]                                     Interaction between *β*1- and *β*2-AR polymorphisms with changes in BMI was observed in men only, while in women an interaction between *β*1- and *β*3-AR polymorphisms was observed in a longitudinal over a 24-year period large cohort study.
                                                                    
  Ethnic difference \[[@B116a], [@B116b]\]                          Distributions of *β*-AR polymorphisms are different in 8 different ethnic populations.
                                                                    
  Haplotype \[[@B20], [@B67], [@B68], [@B113]--[@B115]\]            Functions expressed of *β*-AR polymorphisms are different due to the other *β*-AR polymorphisms.

AR: adrenoceptor; BMI: body mass index.
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